Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
  • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
  • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to the use of a long chain polyunsaturated fatty acid composition for feeding an infant of a mother who suffered from a metabolic disorder during pregnancy and a nutritional composition with polyunsaturated fatty acids suitable for such use.
• DHA docosahexaenoic acid
• n-6 docosapentaenoic acid (DPA n-6) is instead incorporated in the growing brain of the infant. This is undesirable because it is difficult to reverse and may result in impaired neurological development. Additional, insufficient DHA may lead to a hindrance of healthy development .
• DHA deficiency is of particular importance for infants of mothers who suffered from a disease during pregnancy. Hence, particularly for these infants, it is of crucial importance that the infant formula provides an optimal fatty acid profile in the infant.
• DE 4 327 310 describes a milk composition from cows containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and n-3 docosapentaenoic acid (DPA-n3), which is useful for promoting growth, intellectual function and sight function in children.
• the fat composition is however unsuitable for feeding to an infant because the weight ratio linoleic acid/ alpha-linolenic acid (LA/ALA) is not optimal.
• WO 01/78530 describes a nutritional composition containing specified amounts of docosahexaenoic acid (DHA) and arachidonic acid (AA) as well as their precursor essential fatty acids ALA and LA, for providing nutrition and for enhancing neurological development of preterm infants.
• DHA docosahexaenoic acid
• AA arachidonic acid
• WO 2004/052115 describes glyceride compositions, methods of making the glyceride compositions, and nutritional formulations containing the glyceride compositions.
• the glyceride compositions contain predominantly monoglycerides and diglycerides carrying one or more long chain polyunsaturated fatty acids. Also disclosed are methods of using the glyceride compositions and nutritional formulations
• WO 98/36745 describes methods and compositions for reducing the incidence of necrotizing enterocolitis. Said compositions provide n-6 and n-3 long-chain polyunsaturated fatty acids.
• the object of the present invention is to provide a nutritional composition with polyunsaturated fatty acids suitable for feeding an infant of a mother who suffered from a metabolic disorder during pregnancy.
• the present inventors believe that not only DHA and AA need to be abundantly present in infant formula for optimal brain development, but also the precursors of these fatty acids are essential because an important part of the DHA and AA are locally synthesized in the brains from its precursors. Hence, the present inventors believe that addition of DHA and/or AA alone to the standard infant formulas is insufficient to provide optimal DHA incorporation in the various neurological tissues. Hence the present composition also contains, besides DHA and AA, significant amounts of precursors of DHA and AA.
• the present composition contains the precursors of DHA, including at least alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and n-3 docosapentaenoic acid (DPA-n3).
• ALA alpha-linolenic acid
• EPA eicosapentaenoic acid
• DPA-n3 docosapentaenoic acid
• EPA cannot be included in thecomposition in to high amounts, as EPA inhibits the metabolic conversion of linolenic acid (LA) to AA, another important fatty acid.
• LA linolenic acid
• DPAn-3 docosapentaenoic acid
• Both precursors are essential, because they are believed to provide the precursors, which stimulate the local DHA synthesis.
• the weight EPA/DHA ratio in the present composition is between 0.05 and 1 , which is similar or a little below the ratio of the average human milk;
• the weight ratio long chain DHA precursor [DPAn-3 + EPA] per DHA is preferably between 0.25 and 1 in order to provide sufficient DHA precursor;
• the weight ratio DPA-n3/EPA of the present composition is between 0.25 and 5.
• Human milk generally has a weight ratio DPA-n3/EPA above about 1.
• High DPAn-3 oils which can be suitably used, include marine oils such as seal oil and DPAn-3-enriched fish oils.
• the present composition has a weight ratio DHA/DPAn-3 of between 2 and 25, slightly above the average content weight ratio DHA/DPA-n3 in human milk, but a major improvement over the available infant formula containing no or only trace amounts of DPA-n3.
• ALA is added in significant amounts to further reduce insufficiency of DHA.
• the ratio ALA/DHA in the present composition is preferably between 5 and 25.
• arachidonic acid is included in the present composition, particularly in those compositions containing long chain precursors of docosahexaenoic acid.
• AA is an omega-6 fatty acid derived from linoleic acid and is found primarily in food sources such as meat, eggs and milk.
• AA contains twenty carbon atoms and four double bonds (20:4n-6) and is the principal omega-6 fatty acid found in the brain.
• the lipid contains significant amounts of AA precursor, i.e. gamma linolenic acid (GLA) and linoleic acid (LA). These fatty acids provide the precursor for local synthesis of AA.
• GLA gamma linolenic acid
• LA linoleic acid
• the present composition has a high GLA content, i.e. preferably between 0.05 and 0.4 wt.% GLA based on total weight of the lipid, the present composition has a low linoleic acid content, i.e. between 10 and 15 wt.% LA based on total weight of the lipid.
• the present invention provides a nutritional composition wherein the carbohydrate provides 40 to 75 % of the total calories, the lipid provides 20 to 50 % of the total calories and the protein provides 5 to 12.5 % of the total calories, wherein the lipid contains at least one vegetable lipid source and a n-3 docosapentaenoic acid (DPAn-3) containing lipid source, said lipid contains an n-3 polyunsaturated fatty acid fraction and an n-6 polyunsaturated fatty acid fraction, wherein
• DPAn-3 docosapentaenoic acid
• n-3 polyunsaturated fatty acid fraction contains
• DHA docosahexaenoic acid
• DPAn-3 based on total weight of the lipid
• EPA eicosapentaenoic acid
• the sum DHA, DPAn-3 and EPA is below 1 wt.% of total lipid
• ALA alpha linoleic acid
• DHA/DPAn-3 between 2 and 25; ALA/DHA between 5 and 25,
• n-6 polyunsaturated fatty acid fraction contains
• LA linoleic acid
• the present composition which can be considered as a nutrition containing a lipid blend, can suitably be used for feeding healthy infants and is particularly suitable for feeding an infant of a mother who suffered from a metabolic disorder during pregnancy.
• the n-3 polyunsaturated fatty acid fraction as described above provides significant benefits for these infants.
• the composition as described above contains both the n-3 polyunsaturated fatty acid fraction and the n-6 polyunsaturated fatty acid fraction as described herein.
• the present invention provides the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition, which is preferably a liquid composition, for feeding infants of a mother who suffered from a metabolic disorder during pregnancy, said composition comprising a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt % docosahexaenoic acid (DHA) based on total weight of the lipid; and at least 0.01 wt % n-3 docosapentaenoic acid (DPA-n3) based on total weight of the lipid; and at least 0.01 wt.% eicosapentaenoic acid (EPA, n3) based on total weight of the lipid; and wherein the sum DHA, DPA-n3 and EPA is below 1 wt.% of total lipid.
• Said nutritional composition can have any form desired and/or suitable for feeding purposes and is preferably in the form of a liquid.
• the present composition is particularly suitable for infants of mothers who suffered from one or more of diabetes type I, diabetes type II, overweight and obesity during pregnancy. These metabolic disorders are a particular cause of reduced DHA and/or DHA precursor transmittal of the mother to the infant and may result in increased DPAn-6 incorporation into the brain membranes.
• the present composition contains a n-3 polyunsaturated fatty acid fraction comprising at least 0.1 wt %, preferably between 0.10 and 1 wt. %, more preferably between 0.15 and 0.5 wt.% DHA based on total weight of the lipid.
• the present composition contains at least 0.01 wt %, preferably between 0.015 and 0.5 wt.% DPAn-3 based on total weight of the lipid.
• the EPA content is at least 0.01 wt.%, preferably between 0.03 and 0.5 wt.%, even more preferably between 0.04 and 0.1 wt.% based on total weight of the lipid.
• the cumulative weight % (sum) of DHA, DPA and EPA in the present composition is below 1 wt.%, preferably below 0.5 wt.% of total lipid.
• the present composition has a weight ratio EPA/DHA between 0.05 and 1 , preferably between 0.1 and 0.5, more preferably between 0.2 and 0.5.
• the weight ratio DHA/DPAn-3 of the present composition is between 2 and 25, preferably between 5 and 15.
• EPA/DHA of the present composition is between 0.25 and 1. More optimally, the weight ratio (precursors of DHA/DHA), i.e. (DPAn-3 + EPA)/DHA, is between 0.3 and 0.5. In mothers milk, the weight ratio
• DPAn-3/EPA is generally greater than 1.
• the present composition preferably has a weight ratio DPAn-3/EPA between 0.25 and 5, more preferably between 0.3 and 3.
• Particular DPAn-3-enriched fish oils, selected seal oils and biotechnologically produced high DPAn-3 oils may suitably be used for making the composition according to the present invention.
• the present composition contains between 1.9 and 3 wt.%, preferably between 2 and 2.5 wt.% ALA based on total weight of the lipid.
• the wt.% ALA is slightly increased compared to mother's milk.
• Mothers milk generally contains between about 0.5 and 1.6 wt.% ALA based on total weight of the lipid.
• mothers milk generally contains an increased weight percentage of long chain precursors of DHA, e.g. DPAn3 and EPA.
• the weight ratio ALA/DHA is higher in the present composition compared to mother's milk, i.e. between 5 and 25 in the present composition, versus about 2 in mother's milk.
• the ratio ALA/DHA in the present composition is between 7.5 and 15.
• the present composition contains between 0.2 and 1 wt.%, preferably between 0.25 and 0.75 wt.% AA based on total weight of the lipid. AA cannot be incorporated into the composition in to high amounts because of its pro-inflammatory effects.
• the present composition preferably contains between 0.05 and 1 wt.%, preferably between 0.1 and 0.4 wt.%, more preferably between 0.15 and 0.3 wt.% GLA based on total weight of the lipid.
• the high content of GLA is included in the present composition to at least partially compensate for the reduced amount of DGLA in the present composition compared to human milk.
• the present composition contains a high amount of LA, i.e.
• the weight ratio LA/ALA in the present composition is between 5 and 10.
• infant nutrition relates to nutritional formula suitable for feeding to an infant, i.e. nutritional compositions wherein the carbohydrate provides 40 to 75 %, the lipid provides 20 to 50 % and the protein provides 5 to 12.5 % of the total calories.
• the protein provides 7.5 to 12.5 % of the total calories.
• the present composition contains at least one vegetable lipid source and a DPAn-3 containing lipid source. More preferably, the present composition contains at least one lipid source selected from the group consisting of evening primrose oil, borage oil and blackcurrant seed oil; at least one lipid source selected from the group consisting of canola oil, sunflower oil, coconut oil, palm oil and soybean oil; and at least one DPAn-3 containing lipid source. In a further preferred embodiment, the present composition also contains a fungal oil.
• the DPAn-3 containing lipid source contains at least 1 wt.%, even more preferably at least 2 wt.% DPA n-3 based on fatty acids of the DPAn-3 containing lipid source.
• the DPAn-3 containing lipid source contains at least 15 wt.%, more preferably at least 20 wt.% DHA, even more preferably at least 25 wt.% DHA based on fatty acids of the DPAn-3 containing lipid source.
• the present invention provides a method for treating infants of a mother who suffered from a metabolic disorder during pregnancy by administering the present composition.
• lipid sources For the preparation of the present composition, a blend of animal and vegetable lipid sources is used. Because the fatty acid constitution of lipid sources can vary significantly (even if obtained from the same plant or animal source), it is best to first analyze the lipid source to be used and than calculate the amounts of individual oils that are needed to achieve the present composition and admix the lipid sources. Alternatively, the skilled person can find the appropriated lipid sources in proper handbooks.
• the lipid source used are preferably of non-human origin.
• the fatty acids as described in the present invention may be provided as free fatty acids, in triglyceride form, in phospholipid form, or as a mixture of one of more of the above.
• the carbohydrate of the present composition is preferably provided mainly by lactose, because it is most suitable for feeding the infant.
• the digestible carbohydrate fraction (carbohydrate) preferably contains at least 50 wt.%, more preferably at least 90 wt.% lactose based on total weight of the carbohydrate fraction.
• the infant preferably has reduced intestinal discomfort.
• Water-soluble indigestible fibers contribute a reduced occurrence of intestinal discomfort such as bloating.
• the present composition preferably also contains between 0.2 and 5 grams water-soluble indigestible fiber per 100 kcal of the present composition, more preferably between 0.5 and 1.5 gram per 100 kcal.
• the present composition contains at least one water-soluble indigestible fiber selected from the group consisting of galactooligosaccharide, fructooligosaccharide and inulin.
• the present invention particularly relates to nutritional formulas, which are optimally suitable for feeding during the first few months of life.
• a caloric content of between 0.600 and 0.800 kcal per ml is believed to reduce intestinal discomfort in these young infants and thereby stimulate the uptake of fatty acids.
• the present composition preferably contains between 0.600 - 0.800 kcal/ml, more preferably 0.650-0.680 kcal/ml.
• the present invention preferably comprises nucleotides.
• the present composition preferably also comprises between 2 and 25 mg nucleotides and/or between 2 and 25 mg nucleosides per 100 kcal, more preferably between 3 and 10 mg nucleotides per 100 kcal.
• the present composition preferably contains at least 2 nucleotides selected from the group consisting of cytidine-5-monophosphate, uridine-5-monophosphate, adenosine-5-monophosphate, guanosine-5-monophosphate and inosine- 5-monophosphate.
• the nucleotides and/or nucleosides further stimulate the immune system, acting synergistically with the other ingredients of the present composition.
• Example 1 Infant formula:
• a liquid infant nutrition prepared by admixing 13.9 g powder with water to yield 100 ml final product, said liquid product comprising per 100 ml:
• Lipid 48 en% (containing, based on total weight of the lipid 0.2 wt.% DHA; 0.02 wt.% DPAn-3; 0.05 wt.% EPA; 2.2 wt.% ALA, 0.2 wt.% GLA; 0.35 wt.% AA, 13 wt.% LA)
• Fibre 0.8 g (containing 0.05 g fructopolysaccharide (Raftiline HPTM, Orafti, Tienen, Belgium); 0.55 g transgalactooligosaccharides (Vivinal- GOSTM (Borculo Domo Ingredients, Netherlands); 0.20 g pectin hydrolysate prepared as described in EP1373543, example 1.
• composition further contains choline (6 mg/100 ml) and taurine (6.3 mg/100 ml); minerals and trace elements (including 2 mg zinc/100 ml) and vitamins in amounts in compliance with the international guidelines for infant milk formula.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Mycology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pediatric Medicine (AREA)
• Botany (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Edible Oils And Fats (AREA)
• Medicinal Preparation (AREA)
• Fats And Perfumes (AREA)
• Dairy Products (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Bakery Products And Manufacturing Methods Therefor (AREA)
• Seeds, Soups, And Other Foods (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=34927339

Family Applications (1)

Country Status (18)

Cited By (2)

Families Citing this family (23)

Citations (9)

Family Cites Families (10)

• 2004
  • 2004-11-11 EP EP04026825A patent/EP1656839A1/en not_active Withdrawn
• 2005
  • 2005-11-11 PT PT05813382T patent/PT1809125E/pt unknown
  • 2005-11-11 ES ES05813382T patent/ES2341355T3/es not_active Expired - Lifetime
  • 2005-11-11 NZ NZ554629A patent/NZ554629A/en not_active IP Right Cessation
  • 2005-11-11 CN CN201210004226.XA patent/CN102511818B/zh not_active Expired - Fee Related
  • 2005-11-11 DK DK05813382.8T patent/DK1809125T3/da active
  • 2005-11-11 CA CA2586946A patent/CA2586946C/en not_active Expired - Fee Related
  • 2005-11-11 SG SG200803936-4A patent/SG143274A1/en unknown
  • 2005-11-11 EP EP10153682A patent/EP2191733A1/en not_active Withdrawn
  • 2005-11-11 JP JP2007540596A patent/JP2008519796A/ja active Pending
  • 2005-11-11 AT AT05813382T patent/ATE457656T1/de active
  • 2005-11-11 AU AU2005303903A patent/AU2005303903B2/en not_active Ceased
  • 2005-11-11 UA UAA200706381A patent/UA89207C2/ru unknown
  • 2005-11-11 BR BRPI0517479-1A patent/BRPI0517479B1/pt not_active IP Right Cessation
  • 2005-11-11 DE DE602005019452T patent/DE602005019452D1/de not_active Expired - Lifetime
  • 2005-11-11 RU RU2007121665/13A patent/RU2402927C2/ru not_active IP Right Cessation
  • 2005-11-11 WO PCT/EP2005/012122 patent/WO2006050975A1/en not_active Ceased
  • 2005-11-11 CN CN2005800374672A patent/CN101052316B/zh not_active Expired - Fee Related
  • 2005-11-11 US US11/666,990 patent/US8053471B2/en not_active Expired - Fee Related
  • 2005-11-11 EP EP05813382A patent/EP1809125B1/en not_active Expired - Lifetime
  • 2005-11-11 PL PL05813382T patent/PL1809125T3/pl unknown
• 2011
  • 2011-10-03 US US13/251,399 patent/US8729123B2/en not_active Expired - Fee Related

Patent Citations (9)

Also Published As

Similar Documents

Legal Events